Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-R...
Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
About this item
Full title
Author / Creator
Publisher
Los Angeles, CA: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
Los Angeles, CA: SAGE Publications
Subjects
More information
Scope and Contents
Contents
In this multicenter phase II study, we evaluated the safety and efficacy of imatinib in patients with steroid-resistant chronic graft-versus-host disease (cGVHD) and evaluated the quality of life (QOL) of the enrolled patients using the Short Form 36 (SF-36) health survey questionnaire. Thirty-six patients who were diagnosed with steroid-refractory...
Alternative Titles
Full title
Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_076fcd1f669d40b896741f1495d72e27
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_076fcd1f669d40b896741f1495d72e27
Other Identifiers
ISSN
0963-6897
E-ISSN
1555-3892
DOI
10.1177/09636897221113789
